News

Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization

Strategic prioritization of clinical programs with focus on MT-601 in patients with lymphoma MultiTAA-specific T cell therapies demonstrate clinical safety…

3 months ago

Vector Pharma FZCO Announce Exclusive Distribution Agreement with Ascendis Pharma A/S for Skytrofa (lonapegsomatropin) and Yorvipath (palopegteriparatide) in Gulf Cooperation Council Countries 

DUBAI, United Arab Emirates, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Vector Pharma FZCO (Vector) today announced that it has entered…

3 months ago

Editas Medicine Highlights 2024 Anticipated Milestones and Strategic Priorities at the J.P. Morgan Healthcare Conference

Anticipated 2024 milestones include: present reni-cel clinical data updates mid-year and year-end, initiate the RUBY clinical trial adolescent cohort, establish…

3 months ago

Olema Oncology Nominates OP-3136, an Orally Bioavailable KAT6 Inhibitor, as a Development Candidate

OP-3136 demonstrated potent anti-tumor activity alone and in combination with both palazestrant and CDK4/6 inhibitors in preclinical ER+ breast cancer…

3 months ago

OrthoPediatrics Corp. Announces Preliminary Unaudited Financial Highlights for the Fourth Quarter & Full Year 2023

Issues 2024 financial guidanceWARSAW, Ind., Jan. 08, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a…

3 months ago

Vera Therapeutics Announces Appointment of Industry Veterans Robert Brenner, M.D. as Chief Medical Officer and William D. Turner as Chief Development Officer

Robert M. Brenner Robert M. Brenner, M.D., Chief Medical Officer William D. Turner William D. Turner, Chief Development Officer BRISBANE,…

3 months ago

Alignment Healthcare Delivers 44% Year-Over-Year Membership Growth Following Significant Boost from AEP, Increasing Membership to 155,500

Company provides year-end health plan membership guidance, strengthens conviction of path to adjusted EBITDA breakeven in 2024ORANGE, Calif., Jan. 08,…

3 months ago

Biora Therapeutics Announces Initiation of Phase 1 Clinical Study of BT-600

First-in-human trial of BT-600 drug-device combination, following multiple successful device-only human studies SAD/MAD study to evaluate safety and PK/PD of…

3 months ago

Nuclear Medicine/ Radiopharmaceutical/Logistic – Loos, France, RLG, Isovital Headquarter, Jan 8th 2024 : “Life Couriers acquires Isovital and the RLG group to create the global logistic leader for radiopharmaceuticals transportation”.

“Life Couriers acquires RLG to create the global logistic leader for radiopharmaceuticals transportation”. Philippe Sueur, Isovital President stated: « Significant efforts were…

3 months ago

EDAP Announces Preliminary Fourth Quarter Record Focal One® System Sales and Placements

Company reports preliminary placement results of twelve Focal One Systems, inclusive of ten capital sales LYON, France, January 8, 2024…

3 months ago